Association of expression to ERBB-2 nuclear with kidney cancer advanced.

CORTES MA; CORDO RUSSO RI; BARBÁS NCM; QUENARDELLE MA; MADERA S; CHERVO MF; CHIAUZZI VA; CHARREAU EH; GEROMETTA R; ELIZALDE PV

Mar del Plata

Congreso; LXI Reunión Annual de SAIC (Soc. Arg. de Investigaciones Clínicas); 2016

SAIC

The renal cell carcinoma is refractory to chemotherapy andradiotherapy. The major subtype of RCC that metastasize are clearcell and papillary RCC. When it is in advanced stages, decreasedsurvival, and not always respond to kinase inhibitor therapy. In thiscontext, we explored the expression and localization of ErbB-2 andits relationship with the advance RCC. The techniques used wereimmunohistochemistry, Western Blot and Inmunocytofluorescenceconfocal microscopy. We selected 50 paraffin- embedded tissuesamples from a cohort of archived CCR from the files of the Histolopathologyof Vidal Hospital, Corrientes from 2005 to 2015. Theexperiment in vitro basal and HRG stimulation they were performedwith cell lines 786-O (RCC) and HEK-293 (Embryonic Kidney). Ourresults show that, the expression to membrane ErbB-2 (MErbB-2)is of 40% (20/50) only Clear cell RCC, are not expression MErbB-2in Oncocytoma and Papilar RCC. However, it is not related to thestage and histological grade (Chi-square test P=0.8, Stage I vs IIIy IV). We show that nuclear ErbB2 (NErbB-2) is correlated withhistologic grade (Fuhrman Nuclear Grade, FNG) (Chi-square test**P=0.007 FNG 1 vs 2 y 3). Here, we explored ErbB3 expressionbecause we found in the correlation analysis ErbB3 and ErbB2mRNA expression (TCGA Renal datasets in Oncomine ResearchEdition). Our results show relationship between NErbB-3 andNErbB-2, in tissue samples and in vitro in 786-O cells with HRGstimulation. Furthermore, In vitro experiments confocal showNErbB2 and NErbB3 with HRG in 786-O (t-test **P=0.01). Ourfindings showed ErbB-2 is implicated in the carcinogenesis renal.Is very important to localization ErbB-2, because in the clear cellrenal cell carcinoma, ErbB-2 nuclear It is associated with poorprognosis. Our challenge is elucidate the molecular mechanismsof partner ErbB-2/ErbB-3 in renal cell carcinoma.